

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/248196 A1

(43) International Publication Date
16 December 2021 (16.12.2021)

(51) International Patent Classification:

A61K 33/18 (2006.01) *A61P 31/12* (2006.01)
A61K 31/79 (2006.01) *A61P 31/14* (2006.01)
A61K 31/045 (2006.01) *A61P 31/16* (2006.01)
A61P 31/04 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/AU2021/050590

(22) International Filing Date:

10 June 2021 (10.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2020901910 10 June 2020 (10.06.2020) AU

(71) Applicant: **FIREBRICK PHARMA LIMITED**

[AU/AU]; Level 10, 440 Collins Street, Melbourne, Victoria 3000 (AU).

(72) Inventors: **MOLLOY, Peter**; 18 White Hills Road, Creswick, Victoria 3363 (AU). **TUCKER, Simon**; 83A Major Crescent, Lysterfield, Victoria 3156 (AU). **GOODALL, Stephen**; 413A Orange Grove Road, BLACKWALL, New South Wales 2256 (AU).

(74) Agent: **DAVIES COLLISON CAVE PTY LTD**; Level 15, 1 Nicholson Street, Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: IMPROVED VIRUCIDAL FORMULATIONS

(57) Abstract: The present invention is directed to PVP-I formulations having enhanced virucidal activity. The formulations are intended for topical administration for treatment and/or decreased risk of microbial infections in subjects. The formulations include PVP-I and other ingredients selected to enhance the virucidal activity of the formulation over PVP-I alone.

WO 2021/248196 A1